EU gives positive opinion on EpiCepts Ceplene in AML « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
July 2008

M T W T F S S

« Jun Aug »

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30 31

EU gives positive opinion on EpiCepts Ceplene in AML

Posted on July 25, 2008 by crimsoncanary

EpiCept have received a positive opinion from the CHMP for Ceplene (histamine dihydrochloride), for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission.

Filed under: gpcr | Tagged: agonist, Ceplene, EpiCept, EpiLeukin, gpcr, Histamine H2, Maxamine

« Ambrilia initiate Phase I/II trial of 3-month goserelin in Prostate cancer Astellas publish series of Beta 3 adrenoceptor agonsits »

Leave a Reply